AKT1-E17K mutation
Showing 1 - 25 of >10,000
People Who Have Genetic Changes and Features of Autism: Simons
Recruiting
- 16P11.2 Deletion Syndrome
- +184 more
-
New York, New York
- +1 more
Jan 6, 2023
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)
Recruiting
- EGFR NP_005219.2:p.S492R
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Chronic Hand Eczema Trial in Canada, Spain, United Kingdom (Delgocitinib, Cream vehicle)
Recruiting
- Chronic Hand Eczema
- Delgocitinib
- Cream vehicle
-
Darlinghurst, Australia
- +25 more
Dec 12, 2022
Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor Trial (drug, procedure, biological)
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- Locally Advanced Malignant Solid Neoplasm
- Binimetinib
- +22 more
- (no location specified)
Dec 2, 2022
Brodalumab in Plaque Psoriasis to Understand Impact on Quality
Recruiting
- Psoriasis
- Brodalumab
- Matched cohort
-
Calgary, Alberta, Canada
- +33 more
Oct 8, 2022
Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)
Enrolling by invitation
- Autism Spectrum Disorder
- +6 more
- SRS 2, CBCL, BRIEF-P
-
Penrith, New South Wales, Australia
- +57 more
Sep 18, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)
Terminated
- BRAF V600E Mutation Present
- +7 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Mar 9, 2022
Proteus Syndrome Trial run by the NHGRI (MK-7075 (miransertib))
Completed
- Proteus Syndrome
- MK-7075 (miransertib)
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 29, 2022
Locally Advanced or Metastatic Breast Cancer Trial in Canada, Israel, United States (Lasofoxifene, Fulvestrant)
Active, not recruiting
- Locally Advanced or Metastatic Breast Cancer
-
Phoenix, Arizona
- +50 more
Oct 24, 2022
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)
Active, not recruiting
- Advanced Solid Malignancy
- +13 more
-
Los Angeles, California
- +33 more
Dec 22, 2022
Plaque Psoriasis Trial in Canada, United States (Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream)
Completed
- Plaque Psoriasis
- Roflumilast Cream 0.3%
- +2 more
-
Beverly Hills, California
- +29 more
Aug 31, 2022
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)
Recruiting
- HER2-negative Breast Cancer
- +3 more
-
Houston, TexasHouston Methodist Neal Cancer Center
Jan 12, 2023
Parkinson's Disease Trial in Worldwide (venglustat GZ/SAR402671, Placebo)
Terminated
- Parkinson's Disease
- venglustat GZ/SAR402671
- Placebo
-
Scottsdale, Arizona
- +51 more
May 3, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in Worldwide (Obinutuzumab, Venetoclax, Fludarabine)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Obinutuzumab
- +5 more
-
Aurora, Colorado
- +55 more
Jan 30, 2023
Scalp Psoriasis Trial in Canada, United States (ARQ-154 Foam 0.3%, ARQ-154 Vehicle)
Completed
- Scalp Psoriasis
- ARQ-154 Foam 0.3%
- ARQ-154 Vehicle
-
Scottsdale, Arizona
- +48 more
Aug 4, 2022
NSCLC, Colorectal Cancer, Advanced Solid Tumors Trial in Worldwide (GDC-6036, Atezolizumab, Cetuximab)
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
- GDC-6036
- +6 more
-
Duarte, California
- +68 more
Jan 10, 2023
Atopic Dermatitis Eczema Trial in Canada, United States (ARQ-151 Active, ARQ-151 Vehicle)
Active, not recruiting
- Atopic Dermatitis Eczema
- ARQ-151 Active
- ARQ-151 Vehicle
-
Montgomery, Alabama
- +48 more
Aug 10, 2022
Chronic Lymphocytic Leukemia Trial in Worldwide (Venetoclax)
Completed
- Chronic Lymphocytic Leukemia
-
Louisville, Kentucky
- +66 more
Nov 9, 2022
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +13 more
-
Edmonton, Alberta, Canada
- +9 more
Jan 9, 2023
Atopic Dermatitis Eczema Trial in Canada, United States (ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%)
Recruiting
- Atopic Dermatitis Eczema
- ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
-
Birmingham, Alabama
- +91 more
Jan 26, 2023
Advanced NSCLC, Metastatic NSCLC Trial in Worldwide (MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab)
Recruiting
- Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
- MRTX849 Monotherapy
- +2 more
-
Prescott Valley, Arizona
- +134 more
Jan 25, 2023
Activated PI3K-delta Syndrome, Immunodeficiency Primary Trial in Shanghai (Rapamycin)
Recruiting
- Activated PI3K-delta Syndrome
- Immunodeficiency Primary
-
Shanghai, Shanghai, China
- +1 more
Mar 21, 2022
Seborrheic Dermatitis Trial in Canada, United States (ARQ-154 - Active, ARQ-154 Vehicle)
Completed
- Seborrheic Dermatitis
- ARQ-154 - Active
- ARQ-154 Vehicle
-
Scottsdale, Arizona
- +52 more
Aug 4, 2022